Want to see HK:6639 full AI Analyst Report?
6639 Stock Chart & Stats
HK$1.83
HK$0.01(0.41%)
At close: 4:00 PM EST
HK$1.83
HK$0.01(0.41%)
Day’s Range― - ―
52-Week RangeHK$1.59 - HK$2.42
Previous CloseN/A
Volume869.00K
Average Volume (3M)0.00
Market Cap
HK$1.03B
Enterprise ValueHK$1.38B
Total Cash (Recent Filing)HK$1.09B
Total Debt (Recent Filing)HK$1.03B
Price to Earnings (P/E)31.3
Beta1.42
Next Earnings
Dec 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.05
Shares Outstanding564,030,940
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio1.06
Price to Book (P/B)0.47
Price to Sales (P/S)0.47
P/FCF Ratio4.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.08
Revenue Forecast (FY)HK$1.87B
Bulls Say, Bears Say
Bulls Say
Strong Cash GenerationConsistent positive operating and free cash flow, with FCF up about 21% in 2025 and FCF ~0.75x net income, gives the business durable internal funding. This reduces reliance on external finance, supports reinvestment in clinics and tech, and underpins a credible turnaround.
Improved Balance SheetEquity recovery from prior negative levels and manageable leverage (~0.6x debt/equity) materially lowers insolvency risk and improves financial flexibility. A healthier balance sheet supports capex for clinic expansion and cushions operational volatility over the medium term.
Premium Market PositioningA focused premium brand in major Chinese cities, with specialized services (implants, orthodontics) and membership-driven repeat visits, creates structural pricing power and customer loyalty. This market position supports sustainable demand and higher-margin service mix over time.
Bears Say
Very Thin ProfitabilityExtremely low net margins and ROE leave the business exposed: small cost increases or volume declines can wipe out profits. Thin earnings power constrains reinvestment, limits ability to build reserves, and makes sustained improvement dependent on structural margin expansion.
Softening Revenue TrendA declining top line into 2025 undermines scale economics in clinics where fixed costs are material. Soft revenue reduces pricing leverage, pressures gross margins, and slows the translation of positive cash flow into durable profit growth absent a sustained recovery in patient volumes.
Governance And Audit ProbeAn independent forensic probe, auditor resignation and replacement, plus delayed disclosures and suspended trading create material governance, legal and reputational risks. These issues impede access to capital, distract management, and may depress patient/partner confidence over months.
Arrail Group Ltd. News
6639 FAQ
What was Arrail Group Ltd.’s price range in the past 12 months?
Arrail Group Ltd. lowest stock price was HK$1.59 and its highest was HK$2.42 in the past 12 months.
What is Arrail Group Ltd.’s market cap?
Arrail Group Ltd.’s market cap is HK$1.03B.
When is Arrail Group Ltd.’s upcoming earnings report date?
Arrail Group Ltd.’s upcoming earnings report date is Dec 01, 2026 which is in 84 days.
How were Arrail Group Ltd.’s earnings last quarter?
Arrail Group Ltd. released its earnings results on Jun 27, 2025. The company reported HK$0.025 earnings per share for the quarter.
Is Arrail Group Ltd. overvalued?
According to Wall Street analysts Arrail Group Ltd.’s price is currently Overvalued.
Does Arrail Group Ltd. pay dividends?
Arrail Group Ltd. does not currently pay dividends.
What is Arrail Group Ltd.’s EPS estimate?
Arrail Group Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arrail Group Ltd. have?
Arrail Group Ltd. has 564,030,940 shares outstanding.
What happened to Arrail Group Ltd.’s price movement after its last earnings report?
Arrail Group Ltd. reported an EPS of HK$0.025 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Arrail Group Ltd.?
Currently, no hedge funds are holding shares in HK:6639
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arrail Group Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
Company Description
Arrail Group Ltd.
Arrail Group Limited is a Chinese healthcare provider that manages a network of dental clinics and hospitals. It conducts its operations primarily through two brand identities: Arrail Dental and Rytime Dental. The company delivers a comprehensive suite of dental services, including general dental care, orthodontics, and implantology. As of March 21, 2022, its extensive network consisted of 51 clinics operating under the Arrail Dental name, in addition to 54 clinics and seven hospitals functioning under the Rytime Dental brand. Headquartered in Beijing, China, the firm was founded in 1999.
Technical Analysis
EuroEyes International Eye Clinic Limited
―
Chaoju Eye Care Holdings Ltd.
―
Yonghe Medical Group Co., Ltd.
―
Beauty Farm Medical & Health Industry, Inc.
―
C-MER Eye Care Holdings Limited
―